Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

lation phase, expected during the second quarter of 2014, with final study results expected in the second half of 2014. Future development plans for BL-8040 include entering into additional hematological indications, including the commencement of clinical studies in stem cell mobilization and chronic myeloid leukemia during the first half of 2014."

Dr. Gautam Borthakur, the principal investigator from the world-renowned MD Anderson Cancer Center in Houston, stated, "AML is a disease with a clear need for new and more effective treatments. Current options are rather limited, and the five-year survival rate is low compared to many other blood cancers. This is particularly true with respect to patients with relapsed or refractory diseases. The initial results of the BL-8040 Phase 2 trial show a remarkable apoptotic effect of the drug on AML cancer cells, and the drug is exceptional in its ability to induce both mobilization of cancer cells from the bone marrow, as well as a concomitant cell death effect. I therefore have high hopes that this drug will become an important addition to the limited drug arsenal for AML treatment."

About BL-8040
BL-8040 is a clinical-stage drug candidate for the treatment of acute myeloid leukemia and other hematological indications. It is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in retention of cancer cells in the bone marrow, tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity. In a Phase 1/2, open-label, dose escalation, safety and efficacy clinical trial in 18 multiple myeloma patients, BL-8040 demonstrated an excellent safety profile at all doses tested and was high
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  Misonix, Inc. (NASDAQ: MSON ... manufactures and markets innovative therapeutic ultrasonic products for ... surgery, laparoscopic surgery and other surgical applications, announced ... the third quarter fiscal year 2015 on Thursday, ... conference call that same day, Thursday, May 7, ...
(Date:5/1/2015)... 2015  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: ... following the results of the Phase 3 Rocket 1 ... trial failing to meet its end points, compelling data ... from future studies. An analyst report on ... financial review, analyst summary, valuation, and recommendation can be ...
(Date:4/30/2015)... Calif., April 30, 2015 Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... GAAP results: Revenue for the first quarter of 2015 ... the first quarter of 2014, and down $5.3 million ... First quarter 2015 net income as reported in ...
Breaking Medicine Technology:Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27
... that a new market research report is available in its ... 2017 http://www.reportlinker.com/p0333693/Europe-ENT-Devices-Market-Outlook-to-2017.html ... Summary GlobalData,s new report, "Europe ENT Devices ... Europe ENT Devices market – France, Germany, Italy, Spain and ...
... 20, 2011 Boston Scientific Corporation (NYSE: BSX ... March 31, 2011, as well as net sales and earnings ... guidance for the full year 2011. The Company exceeded its ... EPS guidance for the full year 2011. First quarter GAAP ...
Cached Medicine Technology:Reportlinker Adds Europe ENT Devices Market Outlook to 2017 2Reportlinker Adds Europe ENT Devices Market Outlook to 2017 3Reportlinker Adds Europe ENT Devices Market Outlook to 2017 4Reportlinker Adds Europe ENT Devices Market Outlook to 2017 5Reportlinker Adds Europe ENT Devices Market Outlook to 2017 6Reportlinker Adds Europe ENT Devices Market Outlook to 2017 7Reportlinker Adds Europe ENT Devices Market Outlook to 2017 8Reportlinker Adds Europe ENT Devices Market Outlook to 2017 9Reportlinker Adds Europe ENT Devices Market Outlook to 2017 10Reportlinker Adds Europe ENT Devices Market Outlook to 2017 11Reportlinker Adds Europe ENT Devices Market Outlook to 2017 12Reportlinker Adds Europe ENT Devices Market Outlook to 2017 13Boston Scientific Announces Results for First Quarter Ended March 31, 2011 2Boston Scientific Announces Results for First Quarter Ended March 31, 2011 3Boston Scientific Announces Results for First Quarter Ended March 31, 2011 4Boston Scientific Announces Results for First Quarter Ended March 31, 2011 5Boston Scientific Announces Results for First Quarter Ended March 31, 2011 6Boston Scientific Announces Results for First Quarter Ended March 31, 2011 7Boston Scientific Announces Results for First Quarter Ended March 31, 2011 8Boston Scientific Announces Results for First Quarter Ended March 31, 2011 9Boston Scientific Announces Results for First Quarter Ended March 31, 2011 10Boston Scientific Announces Results for First Quarter Ended March 31, 2011 11Boston Scientific Announces Results for First Quarter Ended March 31, 2011 12Boston Scientific Announces Results for First Quarter Ended March 31, 2011 13Boston Scientific Announces Results for First Quarter Ended March 31, 2011 14Boston Scientific Announces Results for First Quarter Ended March 31, 2011 15Boston Scientific Announces Results for First Quarter Ended March 31, 2011 16Boston Scientific Announces Results for First Quarter Ended March 31, 2011 17Boston Scientific Announces Results for First Quarter Ended March 31, 2011 18
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... May 01, 2015 Royal River Natural ... Maine, reports on a new study that found two ... swelling and improved physical function as well as standard ... osteoarthritis of the knee. , The report is part ... for Well Being® ,” which Royal River Natural Foods ...
(Date:5/1/2015)... TROY Healthcare Solutions is proud to ... Group (RUG) Conference in Atlanta, GA from May 6 ... Conference provides a forum for client-to-client presentations, continuing education ... of electronic medical record operations, as well as showcasing ... In addition to sponsoring the event, TROY Healthcare Solutions ...
(Date:5/1/2015)... Hope For The Warriors® thanks All ... The Warriors® and military families. All American Ford presented ... The Warriors®, a national nonprofit dedicated to restoring a ... hope for our service members and our military families. ... collected and matched small autograph fee from fans and ...
(Date:5/1/2015)... Yorba Linda, CA (PRWEB) May 01, 2015 ... of our genetic makeup and the interplay of genes ... Keeping up with developments can be daunting. , LabRoots, ... sciences and clinical diagnostics professionals, will soon host its ... Genomics. , At BioConference Live Genetics and Genomics ...
Breaking Medicine News(10 mins):Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3
... HealthPartners hosts nine physicians from Chongqing Bureau ... HealthPartners,Institute for Medical Education is hosting ... ever to visit Minnesota. During their,three-month stay, ... care, learn about health plan and hospital ...
... 5pm Today, LAWRENCE, Mass., May 12 NxStage ... innovative dialysis products,today announced its financial results for the ... first quarter of 2008 were $31.0 million, compared to,$8.4 ... million in the fourth,quarter of 2007. Revenues in the ...
... heart failure in those with Duchenne muscular dystrophy , , ... muscular dystrophy often suffer from heart failure, but Viagra ... a new Canadian study finds. , In experiments with ... by preventing the breakdown of a compound called cGMP, ...
... impact and other influences are limiting the growth ... of frequency and severity of ... AOC ),the leading provider of global risk management and consulting ... care industry,finding for the first time in nine years of ...
... China, May 12 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., ... modernized traditional Chinese medicine ("TCM") based in,Chengdu, China, ... Roth Third,Annual China Discovery Tour on Tuesday, May ... will be held at the Regent Hotel in ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the nation,s ... it is scheduled to,present from 2:30 p.m. to 2:55 ... Investment Research Global Health Care Conference in New York., ... via a live audio web,cast, which may be accessed ...
Cached Medicine News:Health News:First Major Chinese Medical Delegation Visits Minnesota 2Health News:NxStage Medical Reports First Quarter 2008 Results 2Health News:NxStage Medical Reports First Quarter 2008 Results 3Health News:NxStage Medical Reports First Quarter 2008 Results 4Health News:NxStage Medical Reports First Quarter 2008 Results 5Health News:NxStage Medical Reports First Quarter 2008 Results 6Health News:NxStage Medical Reports First Quarter 2008 Results 7Health News:NxStage Medical Reports First Quarter 2008 Results 8Health News:NxStage Medical Reports First Quarter 2008 Results 9Health News:NxStage Medical Reports First Quarter 2008 Results 10Health News:NxStage Medical Reports First Quarter 2008 Results 11Health News:Viagra May Protect Hearts of Some Muscular Dystrophy Patients 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 3Health News:Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3
... The NGAL ELISA Kit is intended ... fluids, (e.g. plasma, serum, urine), tissue extracts ... is dramatically increased, especially in urine, as ... and in ongoing renal repair processes. NGAL ...
... Light Head is commonly found in Heart rooms where ... the third light head being used to illuminate the ... is also a favorite in trauma rooms should there ... the same time. With 137,000 Lux output per ...
... the only medical grade DVD recorder that features ... two exclusive features DVORECOVERY™ and DVOFAST™, making this ... ever designed. DVORECOVERY enables the end user to ... outage. DVOFAST enables you to remove a recorded ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Medicine Products: